Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 29 entries
Sorted by: Best Match Show Resources per page
Overcoming the Gas-Liquid Mass Transfer of Oxygen by Coupling Photosynthetic Water Oxidation with Biocatalytic Oxyfunctionalization.

Angewandte Chemie (International ed. in English)

Hoschek A, Bühler B, Schmid A.
PMID: 28945948
Angew Chem Int Ed Engl. 2017 Nov 20;56(47):15146-15149. doi: 10.1002/anie.201706886. Epub 2017 Oct 27.

Gas-liquid mass transfer of gaseous reactants is a major limitation for high space-time yields, especially for O

Cite
Hoschek A, Bühler B, Schmid A. Overcoming the Gas-Liquid Mass Transfer of Oxygen by Coupling Photosynthetic Water Oxidation with Biocatalytic Oxyfunctionalization. Angew Chem Int Ed Engl. 2017;56(47):15146-15149doi: 10.1002/anie.201706886.
Hoschek, A., Bühler, B., & Schmid, A. (2017). Overcoming the Gas-Liquid Mass Transfer of Oxygen by Coupling Photosynthetic Water Oxidation with Biocatalytic Oxyfunctionalization. Angewandte Chemie (International ed. in English), 56(47), 15146-15149. https://doi.org/10.1002/anie.201706886
Hoschek, Anna, et al. "Overcoming the Gas-Liquid Mass Transfer of Oxygen by Coupling Photosynthetic Water Oxidation with Biocatalytic Oxyfunctionalization." Angewandte Chemie (International ed. in English) vol. 56,47 (2017): 15146-15149. doi: https://doi.org/10.1002/anie.201706886
Hoschek A, Bühler B, Schmid A. Overcoming the Gas-Liquid Mass Transfer of Oxygen by Coupling Photosynthetic Water Oxidation with Biocatalytic Oxyfunctionalization. Angew Chem Int Ed Engl. 2017 Nov 20;56(47):15146-15149. doi: 10.1002/anie.201706886. Epub 2017 Oct 27. PMID: 28945948; PMCID: PMC5708270.
Copy Download .nbib Format: NLM
Cross-order host switches of hepatitis C-related viruses illustrated by a novel hepacivirus from sloths.

Virus evolution

Moreira-Soto A, Arroyo-Murillo F, Sander AL, Rasche A, Corman V, Tegtmeyer B, Steinmann E, Corrales-Aguilar E, Wieseke N, Avey-Arroyo J, Drexler JF.
PMID: 32704383
Virus Evol. 2020 Apr 25;6(2):veaa033. doi: 10.1093/ve/veaa033. eCollection 2020 Jul.

The genealogy of the hepatitis C virus (HCV) and the genus

Cite
Moreira-Soto A, Arroyo-Murillo F, Sander AL, et al. Cross-order host switches of hepatitis C-related viruses illustrated by a novel hepacivirus from sloths. Virus Evol. 2020;6(2):veaa033doi: 10.1093/ve/veaa033.
Moreira-Soto, A., Arroyo-Murillo, F., Sander, A. L., Rasche, A., Corman, V., Tegtmeyer, B., Steinmann, E., Corrales-Aguilar, E., Wieseke, N., Avey-Arroyo, J., & Drexler, J. F. (2020). Cross-order host switches of hepatitis C-related viruses illustrated by a novel hepacivirus from sloths. Virus evolution, 6(2), veaa033. https://doi.org/10.1093/ve/veaa033
Moreira-Soto, Andres, et al. "Cross-order host switches of hepatitis C-related viruses illustrated by a novel hepacivirus from sloths." Virus evolution vol. 6,2 (2020): veaa033. doi: https://doi.org/10.1093/ve/veaa033
Moreira-Soto A, Arroyo-Murillo F, Sander AL, Rasche A, Corman V, Tegtmeyer B, Steinmann E, Corrales-Aguilar E, Wieseke N, Avey-Arroyo J, Drexler JF. Cross-order host switches of hepatitis C-related viruses illustrated by a novel hepacivirus from sloths. Virus Evol. 2020 Apr 25;6(2):veaa033. doi: 10.1093/ve/veaa033. eCollection 2020 Jul. PMID: 32704383; PMCID: PMC7368370.
Copy Download .nbib Format: NLM
Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.

The Lancet. Child & adolescent health

Weiß C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, Flotats-Bastardas M, Stoltenburg C, Hartmann H, Illsinger S, Denecke J, Pechmann A, Müller-Felber W, Vill K, Blaschek A, Smitka M, van der Stam L, Weiss K, Winter B, Goldhahn K, Plecko B, Horber V, Bernert G, Husain RA, Rauscher C, Trollmann R, Garbade SF, Hahn A, von der Hagen M, Kaindl AM.
PMID: 34756190
Lancet Child Adolesc Health. 2021 Oct 28; doi: 10.1016/S2352-4642(21)00287-X. Epub 2021 Oct 28.

BACKGROUND: Given the novelty of gene replacement therapy with onasemnogene abeparvovec in spinal muscular atrophy, efficacy and safety data are limited, especially for children older than 24 months, those weighing more than 8·5 kg, and those who have received...

Cite
Weiß C, Ziegler A, Becker LL, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2021;doi: 10.1016/S2352-4642(21)00287-X.
Weiß, C., Ziegler, A., Becker, L. L., Johannsen, J., Brennenstuhl, H., Schreiber, G., Flotats-Bastardas, M., Stoltenburg, C., Hartmann, H., Illsinger, S., Denecke, J., Pechmann, A., Müller-Felber, W., Vill, K., Blaschek, A., Smitka, M., van der Stam, L., Weiss, K., Winter, B., Goldhahn, K., Plecko, B., Horber, V., Bernert, G., Husain, R. A., Rauscher, C., Trollmann, R., Garbade, S. F., Hahn, A., von der Hagen, M., & Kaindl, A. M. (2021). Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. The Lancet. Child & adolescent health, . https://doi.org/10.1016/S2352-4642(21)00287-X
Weiß, Claudia, et al. "Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study." The Lancet. Child & adolescent health vol. (2021). doi: https://doi.org/10.1016/S2352-4642(21)00287-X
Weiß C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, Flotats-Bastardas M, Stoltenburg C, Hartmann H, Illsinger S, Denecke J, Pechmann A, Müller-Felber W, Vill K, Blaschek A, Smitka M, van der Stam L, Weiss K, Winter B, Goldhahn K, Plecko B, Horber V, Bernert G, Husain RA, Rauscher C, Trollmann R, Garbade SF, Hahn A, von der Hagen M, Kaindl AM. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2021 Oct 28; doi: 10.1016/S2352-4642(21)00287-X. Epub 2021 Oct 28. PMID: 34756190.
Copy Download .nbib Format: NLM
Burden of disease and lifestyle habits in adolescents and young adults prone to frequent episodic migraine: A secondary comparative analysis.

Journal of child health care : for professionals working with children in the hospital and community

Bonfert MV, Sollmann N, Renner T, Börner C, Urban G, Schandelmaier P, Hannibal I, Huß K, Parisi C, Gerstl L, Vill K, Blaschek A, Koenig H, Klose B, Heinen F, Landgraf MN, Albers L.
PMID: 33955272
J Child Health Care. 2021 May 06;13674935211008712. doi: 10.1177/13674935211008712. Epub 2021 May 06.

The objective of this study was to assess the burden of disease and prevalence of lifestyle factors for adolescents and young adults with frequent episodic migraine. We conducted a secondary comparative analysis of data collected during two previous studies....

Cite
Bonfert MV, Sollmann N, Renner T, et al. Burden of disease and lifestyle habits in adolescents and young adults prone to frequent episodic migraine: A secondary comparative analysis. J Child Health Care. 2021;13674935211008712doi: 10.1177/13674935211008712.
Bonfert, M. V., Sollmann, N., Renner, T., Börner, C., Urban, G., Schandelmaier, P., Hannibal, I., Huß, K., Parisi, C., Gerstl, L., Vill, K., Blaschek, A., Koenig, H., Klose, B., Heinen, F., Landgraf, M. N., & Albers, L. (2021). Burden of disease and lifestyle habits in adolescents and young adults prone to frequent episodic migraine: A secondary comparative analysis. Journal of child health care : for professionals working with children in the hospital and community, 13674935211008712. https://doi.org/10.1177/13674935211008712
Bonfert, Michaela V, et al. "Burden of disease and lifestyle habits in adolescents and young adults prone to frequent episodic migraine: A secondary comparative analysis." Journal of child health care : for professionals working with children in the hospital and community vol. (2021): 13674935211008712. doi: https://doi.org/10.1177/13674935211008712
Bonfert MV, Sollmann N, Renner T, Börner C, Urban G, Schandelmaier P, Hannibal I, Huß K, Parisi C, Gerstl L, Vill K, Blaschek A, Koenig H, Klose B, Heinen F, Landgraf MN, Albers L. Burden of disease and lifestyle habits in adolescents and young adults prone to frequent episodic migraine: A secondary comparative analysis. J Child Health Care. 2021 May 06;13674935211008712. doi: 10.1177/13674935211008712. Epub 2021 May 06. PMID: 33955272.
Copy Download .nbib Format: NLM
[Newborn screening program for spinal muscular atrophy].

Der Nervenarzt

Kölbel H, Vill K, Schwartz O, Blaschek A, Nennstiel U, Schara-Schmidt U, Hoffmann GF, Gläser D, Röschinger W, Bernert G, Klein A, Müller-Felber W.
PMID: 34652481
Nervenarzt. 2021 Oct 15; doi: 10.1007/s00115-021-01204-y. Epub 2021 Oct 15.

BACKGROUND: The introduction of a comprehensive newborn screening program for spinal muscular atrophy (SMA), specifically for 5q-SMA, is planned for the end of 2021 in Germany. Several targeted treatment options have become available for all patients with SMA.MATERIAL AND...

Cite
Kölbel H, Vill K, Schwartz O, et al. Neugeborenenscreeningprogramm für die spinale Muskelatrophie. [Newborn screening program for spinal muscular atrophy]. Nervenarzt. 2021;doi: 10.1007/s00115-021-01204-y.
Kölbel, H., Vill, K., Schwartz, O., Blaschek, A., Nennstiel, U., Schara-Schmidt, U., Hoffmann, G. F., Gläser, D., Röschinger, W., Bernert, G., Klein, A., & Müller-Felber, W. (2021). Neugeborenenscreeningprogramm für die spinale Muskelatrophie. [Newborn screening program for spinal muscular atrophy]. Der Nervenarzt, . https://doi.org/10.1007/s00115-021-01204-y
Kölbel, Heike, et al. "Neugeborenenscreeningprogramm für die spinale Muskelatrophie." [Newborn screening program for spinal muscular atrophy]. Der Nervenarzt vol. (2021). doi: https://doi.org/10.1007/s00115-021-01204-y
Kölbel H, Vill K, Schwartz O, Blaschek A, Nennstiel U, Schara-Schmidt U, Hoffmann GF, Gläser D, Röschinger W, Bernert G, Klein A, Müller-Felber W. Neugeborenenscreeningprogramm für die spinale Muskelatrophie. [Newborn screening program for spinal muscular atrophy]. Nervenarzt. 2021 Oct 15; doi: 10.1007/s00115-021-01204-y. Epub 2021 Oct 15. German. PMID: 34652481.
Copy Download .nbib Format: NLM
Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.

The Lancet. Child & adolescent health

Weiß C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, Flotats-Bastardas M, Stoltenburg C, Hartmann H, Illsinger S, Denecke J, Pechmann A, Müller-Felber W, Vill K, Blaschek A, Smitka M, van der Stam L, Weiss K, Winter B, Goldhahn K, Plecko B, Horber V, Bernert G, Husain RA, Rauscher C, Trollmann R, Garbade SF, Hahn A, von der Hagen M, Kaindl AM.
PMID: 34756190
Lancet Child Adolesc Health. 2022 Jan;6(1):17-27. doi: 10.1016/S2352-4642(21)00287-X. Epub 2021 Oct 29.

BACKGROUND: Given the novelty of gene replacement therapy with onasemnogene abeparvovec in spinal muscular atrophy, efficacy and safety data are limited, especially for children older than 24 months, those weighing more than 8·5 kg, and those who have received...

Cite
Weiß C, Ziegler A, Becker LL, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2021;6(1):17-27doi: 10.1016/S2352-4642(21)00287-X.
Weiß, C., Ziegler, A., Becker, L. L., Johannsen, J., Brennenstuhl, H., Schreiber, G., Flotats-Bastardas, M., Stoltenburg, C., Hartmann, H., Illsinger, S., Denecke, J., Pechmann, A., Müller-Felber, W., Vill, K., Blaschek, A., Smitka, M., van der Stam, L., Weiss, K., Winter, B., Goldhahn, K., Plecko, B., Horber, V., Bernert, G., Husain, R. A., Rauscher, C., Trollmann, R., Garbade, S. F., Hahn, A., von der Hagen, M., & Kaindl, A. M. (2022). Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. The Lancet. Child & adolescent health, 6(1), 17-27. https://doi.org/10.1016/S2352-4642(21)00287-X
Weiß, Claudia, et al. "Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study." The Lancet. Child & adolescent health vol. 6,1 (2022): 17-27. doi: https://doi.org/10.1016/S2352-4642(21)00287-X
Weiß C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, Flotats-Bastardas M, Stoltenburg C, Hartmann H, Illsinger S, Denecke J, Pechmann A, Müller-Felber W, Vill K, Blaschek A, Smitka M, van der Stam L, Weiss K, Winter B, Goldhahn K, Plecko B, Horber V, Bernert G, Husain RA, Rauscher C, Trollmann R, Garbade SF, Hahn A, von der Hagen M, Kaindl AM. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2022 Jan;6(1):17-27. doi: 10.1016/S2352-4642(21)00287-X. Epub 2021 Oct 29. PMID: 34756190.
Copy Download .nbib Format: NLM
Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.

The Lancet. Child & adolescent health

Weiß C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, Flotats-Bastardas M, Stoltenburg C, Hartmann H, Illsinger S, Denecke J, Pechmann A, Müller-Felber W, Vill K, Blaschek A, Smitka M, van der Stam L, Weiss K, Winter B, Goldhahn K, Plecko B, Horber V, Bernert G, Husain RA, Rauscher C, Trollmann R, Garbade SF, Hahn A, von der Hagen M, Kaindl AM.
PMID: 34756190
Lancet Child Adolesc Health. 2022 Jan;6(1):17-27. doi: 10.1016/S2352-4642(21)00287-X. Epub 2021 Oct 29.

BACKGROUND: Given the novelty of gene replacement therapy with onasemnogene abeparvovec in spinal muscular atrophy, efficacy and safety data are limited, especially for children older than 24 months, those weighing more than 8·5 kg, and those who have received...

Cite
Weiß C, Ziegler A, Becker LL, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2021;6(1):17-27doi: 10.1016/S2352-4642(21)00287-X.
Weiß, C., Ziegler, A., Becker, L. L., Johannsen, J., Brennenstuhl, H., Schreiber, G., Flotats-Bastardas, M., Stoltenburg, C., Hartmann, H., Illsinger, S., Denecke, J., Pechmann, A., Müller-Felber, W., Vill, K., Blaschek, A., Smitka, M., van der Stam, L., Weiss, K., Winter, B., Goldhahn, K., Plecko, B., Horber, V., Bernert, G., Husain, R. A., Rauscher, C., Trollmann, R., Garbade, S. F., Hahn, A., von der Hagen, M., & Kaindl, A. M. (2022). Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. The Lancet. Child & adolescent health, 6(1), 17-27. https://doi.org/10.1016/S2352-4642(21)00287-X
Weiß, Claudia, et al. "Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study." The Lancet. Child & adolescent health vol. 6,1 (2022): 17-27. doi: https://doi.org/10.1016/S2352-4642(21)00287-X
Weiß C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, Flotats-Bastardas M, Stoltenburg C, Hartmann H, Illsinger S, Denecke J, Pechmann A, Müller-Felber W, Vill K, Blaschek A, Smitka M, van der Stam L, Weiss K, Winter B, Goldhahn K, Plecko B, Horber V, Bernert G, Husain RA, Rauscher C, Trollmann R, Garbade SF, Hahn A, von der Hagen M, Kaindl AM. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2022 Jan;6(1):17-27. doi: 10.1016/S2352-4642(21)00287-X. Epub 2021 Oct 29. PMID: 34756190.
Copy Download .nbib Format: NLM
[On the histology and biology of prostate carcinoma].

Zeitschrift fur Urologie

KOEHLMEIER W, HASCHEK H.
PMID: 14410406
Z Urol. 1960 Jun;53:287-93.

No abstract available.

Cite
KOEHLMEIER W, HASCHEK H. [On the histology and biology of prostate carcinoma]. Z Urol. 1960;53:287-93
KOEHLMEIER, W., & HASCHEK, H. (1960). [On the histology and biology of prostate carcinoma]. Zeitschrift fur Urologie, 53287-93.
KOEHLMEIER, W, and HASCHEK, H. "[On the histology and biology of prostate carcinoma]." Zeitschrift fur Urologie vol. 53 (1960): 287-93.
KOEHLMEIER W, HASCHEK H. [On the histology and biology of prostate carcinoma]. Z Urol. 1960 Jun;53:287-93. German. PMID: 14410406.
Copy Download .nbib Format: NLM
Alternative exon splicing and differential expression in pancreatic islets reveals candidate genes and pathways implicated in early diabetes development.

Mammalian genome : official journal of the International Mammalian Genome Society

Rehman SU, Schallschmidt T, Rasche A, Knebel B, Stermann T, Altenhofen D, Herwig R, Schürmann A, Chadt A, Al-Hasani H.
PMID: 33880624
Mamm Genome. 2021 Jun;32(3):153-172. doi: 10.1007/s00335-021-09869-1. Epub 2021 Apr 20.

Type 2 diabetes (T2D) has a strong genetic component. Most of the gene variants driving the pathogenesis of T2D seem to target pancreatic β-cell function. To identify novel gene variants acting at early stage of the disease, we analyzed...

Cite
Rehman SU, Schallschmidt T, Rasche A, et al. Alternative exon splicing and differential expression in pancreatic islets reveals candidate genes and pathways implicated in early diabetes development. Mamm Genome. 2021;32(3):153-172doi: 10.1007/s00335-021-09869-1.
Rehman, S. U., Schallschmidt, T., Rasche, A., Knebel, B., Stermann, T., Altenhofen, D., Herwig, R., Schürmann, A., Chadt, A., & Al-Hasani, H. (2021). Alternative exon splicing and differential expression in pancreatic islets reveals candidate genes and pathways implicated in early diabetes development. Mammalian genome : official journal of the International Mammalian Genome Society, 32(3), 153-172. https://doi.org/10.1007/s00335-021-09869-1
Rehman, Sayeed Ur, et al. "Alternative exon splicing and differential expression in pancreatic islets reveals candidate genes and pathways implicated in early diabetes development." Mammalian genome : official journal of the International Mammalian Genome Society vol. 32,3 (2021): 153-172. doi: https://doi.org/10.1007/s00335-021-09869-1
Rehman SU, Schallschmidt T, Rasche A, Knebel B, Stermann T, Altenhofen D, Herwig R, Schürmann A, Chadt A, Al-Hasani H. Alternative exon splicing and differential expression in pancreatic islets reveals candidate genes and pathways implicated in early diabetes development. Mamm Genome. 2021 Jun;32(3):153-172. doi: 10.1007/s00335-021-09869-1. Epub 2021 Apr 20. PMID: 33880624; PMCID: PMC8128753.
Copy Download .nbib Format: NLM
Erratum to "Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening - Opportunity or Burden?".

Journal of neuromuscular diseases

Müller-Felber W, Vill K, Schwartz O, Gläser D, Nennstiel U, Wirth B, Burggraf S, Röschinger W, Becker M, Durner J, Eggermann K, Müller C, Hannibal I, Olgemöller B, Schara U, Blaschek A, Kölbel H.
PMID: 33579869
J Neuromuscul Dis. 2021;8(2):335-336. doi: 10.3233/JND-219002.

No abstract available.

Cite
Müller-Felber W, Vill K, Schwartz O, et al. Erratum to "Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening - Opportunity or Burden?". J Neuromuscul Dis. 2021;8(2):335-336doi: 10.3233/JND-219002.
Müller-Felber, W., Vill, K., Schwartz, O., Gläser, D., Nennstiel, U., Wirth, B., Burggraf, S., Röschinger, W., Becker, M., Durner, J., Eggermann, K., Müller, C., Hannibal, I., Olgemöller, B., Schara, U., Blaschek, A., & Kölbel, H. (2021). Erratum to "Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening - Opportunity or Burden?". Journal of neuromuscular diseases, 8(2), 335-336. https://doi.org/10.3233/JND-219002
Müller-Felber, Wolfgang, et al. "Erratum to "Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening - Opportunity or Burden?"." Journal of neuromuscular diseases vol. 8,2 (2021): 335-336. doi: https://doi.org/10.3233/JND-219002
Müller-Felber W, Vill K, Schwartz O, Gläser D, Nennstiel U, Wirth B, Burggraf S, Röschinger W, Becker M, Durner J, Eggermann K, Müller C, Hannibal I, Olgemöller B, Schara U, Blaschek A, Kölbel H. Erratum to "Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening - Opportunity or Burden?". J Neuromuscul Dis. 2021;8(2):335-336. doi: 10.3233/JND-219002. PMID: 33579869; PMCID: PMC8075388.
Copy Download .nbib Format: NLM
Quantitative Motion Measurements Based on Markerless 3D Full-Body Tracking in Children with SMA Highly Correlate with Standardized Motor Assessments.

Journal of neuromuscular diseases

Blaschek A, Hesse N, Warken B, Vill K, Well T, Hodek C, Heinen F, Müller-Felber W, Schroeder AS.
PMID: 34308910
J Neuromuscul Dis. 2021 Jul 21; doi: 10.3233/JND-200619. Epub 2021 Jul 21.

BACKGROUND: Spinal Muscular Atrophy (SMA) is the most common neurodegenerative disease in childhood. New therapeutic interventions have been developed to interrupt rapid motor deterioration. The current standard of clinical evaluation for severely weak infants is the Children's Hospital of...

Cite
Blaschek A, Hesse N, Warken B, et al. Quantitative Motion Measurements Based on Markerless 3D Full-Body Tracking in Children with SMA Highly Correlate with Standardized Motor Assessments. J Neuromuscul Dis. 2021;doi: 10.3233/JND-200619.
Blaschek, A., Hesse, N., Warken, B., Vill, K., Well, T., Hodek, C., Heinen, F., Müller-Felber, W., & Schroeder, A. S. (2021). Quantitative Motion Measurements Based on Markerless 3D Full-Body Tracking in Children with SMA Highly Correlate with Standardized Motor Assessments. Journal of neuromuscular diseases, . https://doi.org/10.3233/JND-200619
Blaschek, Astrid, et al. "Quantitative Motion Measurements Based on Markerless 3D Full-Body Tracking in Children with SMA Highly Correlate with Standardized Motor Assessments." Journal of neuromuscular diseases vol. (2021). doi: https://doi.org/10.3233/JND-200619
Blaschek A, Hesse N, Warken B, Vill K, Well T, Hodek C, Heinen F, Müller-Felber W, Schroeder AS. Quantitative Motion Measurements Based on Markerless 3D Full-Body Tracking in Children with SMA Highly Correlate with Standardized Motor Assessments. J Neuromuscul Dis. 2021 Jul 21; doi: 10.3233/JND-200619. Epub 2021 Jul 21. PMID: 34308910.
Copy Download .nbib Format: NLM
Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.

The Lancet. Child & adolescent health

Weiß C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, Flotats-Bastardas M, Stoltenburg C, Hartmann H, Illsinger S, Denecke J, Pechmann A, Müller-Felber W, Vill K, Blaschek A, Smitka M, van der Stam L, Weiss K, Winter B, Goldhahn K, Plecko B, Horber V, Bernert G, Husain RA, Rauscher C, Trollmann R, Garbade SF, Hahn A, von der Hagen M, Kaindl AM.
PMID: 34756190
Lancet Child Adolesc Health. 2022 Jan;6(1):17-27. doi: 10.1016/S2352-4642(21)00287-X. Epub 2021 Oct 29.

BACKGROUND: Given the novelty of gene replacement therapy with onasemnogene abeparvovec in spinal muscular atrophy, efficacy and safety data are limited, especially for children older than 24 months, those weighing more than 8·5 kg, and those who have received...

Cite
Weiß C, Ziegler A, Becker LL, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2021;6(1):17-27doi: 10.1016/S2352-4642(21)00287-X.
Weiß, C., Ziegler, A., Becker, L. L., Johannsen, J., Brennenstuhl, H., Schreiber, G., Flotats-Bastardas, M., Stoltenburg, C., Hartmann, H., Illsinger, S., Denecke, J., Pechmann, A., Müller-Felber, W., Vill, K., Blaschek, A., Smitka, M., van der Stam, L., Weiss, K., Winter, B., Goldhahn, K., Plecko, B., Horber, V., Bernert, G., Husain, R. A., Rauscher, C., Trollmann, R., Garbade, S. F., Hahn, A., von der Hagen, M., & Kaindl, A. M. (2022). Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. The Lancet. Child & adolescent health, 6(1), 17-27. https://doi.org/10.1016/S2352-4642(21)00287-X
Weiß, Claudia, et al. "Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study." The Lancet. Child & adolescent health vol. 6,1 (2022): 17-27. doi: https://doi.org/10.1016/S2352-4642(21)00287-X
Weiß C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, Flotats-Bastardas M, Stoltenburg C, Hartmann H, Illsinger S, Denecke J, Pechmann A, Müller-Felber W, Vill K, Blaschek A, Smitka M, van der Stam L, Weiss K, Winter B, Goldhahn K, Plecko B, Horber V, Bernert G, Husain RA, Rauscher C, Trollmann R, Garbade SF, Hahn A, von der Hagen M, Kaindl AM. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2022 Jan;6(1):17-27. doi: 10.1016/S2352-4642(21)00287-X. Epub 2021 Oct 29. PMID: 34756190.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 29 entries